Summary

One of the most important advances in the treatment of acute lymphoblastic leukemia (ALL) is the development of monoclonal antibody therapies. Multiple derivatives of this therapy have been developed, each with unique targets and mechanisms of action. This article discusses the monoclonal antibody-based therapies for the treatment of ALL, ALL in older adolescent and young adult patients, and minimal residual disease in ALL.